RTP Mobile Logo
Submitted by web@researchtop... on Tue, 05/21/2013 - 15:40

In these audio proceedings from a closed Think Tank meeting held in February 2013, the invited faculty discuss and debate the current nonprotocol management of early and advanced breast cancer as well as promising research strategies in this area. The roundtable discussion focused on key presentations and papers released over the past year as well as actual cases managed in the practices of the faculty where these data sets factored into their decision-making. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.
 

Listen to audio excerpts

Track 1: Case discussion: A 60-year-old woman with ER-positive, HER2-negative breast cancer (BC) presents with 2 small liver metastases after 12 months of anastrozole for metastatic disease
Track 2: Response, side effects and clinical experience with everolimus/exemestane in ER-positive metastatic BC (mBC)
Track 3: Results of a Phase II trial of everolimus and tamoxifen for ER-positive, HER2-negative mBC
Track 4: Results of a Phase III trial of letrozole in combination with temsirolimus as first-line therapy for postmenopausal women with locally advanced or metastatic ER-positive BC
Track 5: Editorial — “Improving endocrine therapy for BC: It’s not that simple”
Track 6: CONFIRM: Final overall survival analysis of a Phase III trial of low- versus high-dose fulvestrant for ER-positive mBC
Track 7: ALTERNATE trial: Neoadjuvant anastrozole with or without fulvestrant for ER-positive BC
Track 8: Results of a Phase III trial of eribulin versus capecitabine for locally advanced or metastatic BC
Track 9: Sequencing capecitabine and eribulin in the treatment of HER2-negative mBC
Track 10: Therapeutic options for HER2-negative mBC
Track 11: Ongoing Phase II study of the PARP inhibitor veliparib in combination with temozolomide or carboplatin/paclitaxel in BRCA1/2 mutation-positive mBC
Track 12: Current status of PARP inhibitor research in BC
Track 13: Pertuzumab in combination with trastuzumab and docetaxel as first-line therapy for HER2-positive mBC: Overall survival, biomarker analysis and evaluation of elderly patients in the CLEOPATRA study
Track 14: Challenges in identifying predictors of response to anti-HER2-based therapies
Track 15: Use of weekly paclitaxel in combination with pertuzumab/trastuzumab for HER2-positive mBC
Track 16: Potential role for pertuzumab in later-line therapy for HER2-positive mBC
Track 17: PERTAIN: A Phase II study of trastuzumab/taxane or trastuzumab and an aromatase inhibitor with or without pertuzumab as first-line therapy for ER-positive, HER2-positive mBC
Track 18: VELVET: A 2-cohort Phase II trial of vinorelbine/trastuzumab/pertuzumab as first-line therapy for HER2-positive locally advanced or metastatic BC
Track 19: Meta-analysis: Risk of rash with pertuzumab
Track 20: EMILIA study: T-DM1 versus capecitabine and lapatinib for HER2-positive mBC
Track 21: Monitoring and management of T-DM1-associated thrombocytopenia
Track 22: Case discussion: A 52-year-old woman with HER2-positive mBC is enrolled on a T-DM1 arm of the MARIANNE trial
Track 23: MARIANNE: A Phase III trial of T-DM1 with or without pertuzumab versus taxane/trastuzumab for HER2-positive mBC
Track 24: Case discussion: A 55-year-old woman with ER/PR-positive, HER2-negative infiltrating lobular carcinoma desires breast-conserving therapy
Track 25: Use of the Oncotype DX® assay in ER-positive, node-negative BC in the adjuvant and neoadjuvant settings
Track 26: Case discussion: A 76-year-old woman with Grade II, highly ER/PR-positive, HER2-negative infiltrating ductal carcinoma (IDC) and multiple comorbidities
Track 27: Results of the NSABP-B-38 study: Adjuvant dose-dense AC > paclitaxel with or without gemcitabine versus TAC in node-positive BC
Track 28: Case discussion: A healthy 83-year-old woman with a 4.5-cm, Grade III, triple-negative, node-positive BC
Track 29: Case discussion: A 45-year-old woman previously treated for a T1N0 ER/PR-positive, HER2-positive BC presents with a triple-negative ipsilateral BC
Track 30: CALOR (IBCSG 27-02, NSABP-B-37, BIG 1-02) trial: Adjuvant chemotherapy prolongs survival for patients with isolated local or regional recurrence of BC
Track 31: Importance of rebiopsy in patients with recurrent mBC
Track 32: Case discussion: A 58-year-old woman with a 2.2-cm, strongly ER/PR-positive, HER2-negative IDC, 1 of 4 positive sentinel nodes and an Oncotype DX Recurrence Score® of 11
Track 33: Oncotype DX to guide adjuvant chemotherapy decision-making for patients with limited nodal involvement
Track 34: Utility of the Oncotype DX assay in large, node-negative BC
Track 35: NSABP-B-28 study: Prognostic impact of the Oncotype DX Recurrence Score in patients with ER-positive, node-positive BC treated with adjuvant chemotherapy
Track 36: MINDACT: A Phase III trial comparing MammaPrint® to Adjuvant! Online in selecting patients with negative nodes or 1 to 3 positive nodes for adjuvant chemotherapy
Track 37: Results of the ATLAS trial of 5 versus 10 years of adjuvant tamoxifen for women with ER-positive BC
Track 38: Increased incidence of endometrial cancer in postmenopausal women receiving longer-duration adjuvant tamoxifen
Track 39: Reduction in the risk of second BC with longer-duration adjuvant tamoxifen
Track 40: Case discussion: A 37-year-old woman previously treated 11 years ago for a Stage IA, ER/PR-positive, HER2-negative BC with chemotherapy and 5 years of tamoxifen inquires about reinitiating endocrine therapy
Track 41: Results from NSABP-B-41: A Phase III trial of neoadjuvant chemotherapy with trastuzumab, lapatinib and the combination for HER2-positive BC
Track 42: CALGB-40601: A Phase III trial of paclitaxel in combination with trastuzumab or trastuzumab/lapatinib as neoadjuvant therapy for HER2-positive primary BC
Track 43: ALTTO: A Phase III study of adjuvant trastuzumab, lapatinib, the combination or the sequence for HER2-positive primary BC
Track 44: Methodological concerns with neoadjuvant trial designs and endpoints
Track 45: Case discussion: A 48-year-old perimenopausal woman with an ER/PR-negative, HER2-positive IDC
Track 46: Optimal duration of adjuvant trastuzumab
 
FACULTY:
 
Adam M Brufsky, MD, PhD
Professor of Medicine
University of Pittsburgh
Associate Director for Clinical Investigation
University of Pittsburgh Cancer Institute
Co-Director, Comprehensive Breast Cancer Center
Associate Division Chief
University of Pittsburgh
Department of Medicine
Division of Hematology/Oncology
Pittsburgh, Pennsylvania
 
Lisa A Carey, MD
Richardson and Marilyn Jacobs Preyer
Distinguished Professor for Breast Cancer Research
Chief, Division of Hematology
and Oncology
Physician-in-Chief
North Carolina Cancer Hospital
Associate Director for Clinical Research
Lineberger Comprehensive
Cancer Center
Chapel Hill, North Carolina
 
William J Gradishar, MD
Betsy Bramsen Professor of
Breast Oncology
Professor of Medicine
Director
Maggie Daley Center for
Women’s Cancer Care
Robert H Lurie Comprehensive
Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
 
Sara A Hurvitz, MD
Assistant Clinical Professor of Medicine
University of California, Los Angeles
Director, Breast Oncology Program
Medical Director, Clinical Research Unit
Jonsson Comprehensive Cancer Center
Los Angeles, California
 
Monica Morrow, MD
Anne Burnett Windfohr Chair of
Clinical Oncology
Chief of Breast Service
Department of Surgery
Memorial Sloan-Kettering
Cancer Center
Professor of Surgery
Weill Medical College of
Cornell University
New York, New York
 
Ruth O’Regan, MD
Professor and Vice-Chair for
Educational Affairs
Department of Hematology and
Medical Oncology
Chief of Hematology and
Medical Oncology
Georgia Cancer Center for
Excellence at
Grady Memorial Hospital
Louisa and
Rand Glenn Family Chair in
Breast Cancer Research
Winship Cancer Institute of
Emory University
Atlanta, Georgia
 
Edith A Perez, MD
Deputy Director at Large
Mayo Clinic Cancer Center
Group Vice Chair
Alliance of Clinical Trials in Oncology
Serene M and Frances C Durling
Professor of Medicine
Mayo Clinic
Jacksonville, Florida
 
Hope S Rugo, MD
Professor of Medicine
Director
Breast Oncology and
Clinical Trials Education
University of California
San Francisco, Helen Diller Family
Comprehensive Cancer Center
San Francisco, California
 
MODERATOR:
 
Neil Love, MD
Research To Practice
Miami, Florida